- Home
- NRIX vs SENEA Comparison
NRIX vs SENEA Comparison
Compare NRIX & SENEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- SENEA
- Stock Information
- Founded
- NRIX 2009
- SENEA 1949
- Country
- NRIX United States
- SENEA United States
- Employees
- NRIX N/A
- SENEA N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- SENEA Packaged Foods
- Sector
- NRIX Health Care
- SENEA Consumer Staples
- Exchange
- NRIX Nasdaq
- SENEA Nasdaq
- Market Cap
- NRIX 750.4M
- SENEA 710.1M
- IPO Year
- NRIX 2020
- SENEA N/A
- Fundamental
- Price
- NRIX $16.85
- SENEA $123.15
- Analyst Decision
- NRIX Strong Buy
- SENEA
- Analyst Count
- NRIX 14
- SENEA 0
- Target Price
- NRIX $26.29
- SENEA N/A
- AVG Volume (30 Days)
- NRIX 1.8M
- SENEA 96.5K
- Earning Date
- NRIX 10-09-2025
- SENEA 11-05-2025
- Dividend Yield
- NRIX N/A
- SENEA N/A
- EPS Growth
- NRIX N/A
- SENEA 47.79
- EPS
- NRIX N/A
- SENEA 8.61
- Revenue
- NRIX $83,687,000.00
- SENEA $1,606,175,000.00
- Revenue This Year
- NRIX $58.48
- SENEA N/A
- Revenue Next Year
- NRIX N/A
- SENEA N/A
- P/E Ratio
- NRIX N/A
- SENEA $14.24
- Revenue Growth
- NRIX 48.32
- SENEA 8.33
- 52 Week Low
- NRIX $8.18
- SENEA $70.20
- 52 Week High
- NRIX $23.09
- SENEA $126.40
- Technical
- Relative Strength Index (RSI)
- NRIX 80.15
- SENEA 61.26
- Support Level
- NRIX $12.43
- SENEA $119.37
- Resistance Level
- NRIX $13.43
- SENEA $126.40
- Average True Range (ATR)
- NRIX 0.97
- SENEA 5.02
- MACD
- NRIX 0.32
- SENEA 1.15
- Stochastic Oscillator
- NRIX 98.68
- SENEA 85.31
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About SENEA Seneca Foods Corp.
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.